Clinical trials: Nutrition Assessment
Obesity
A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity
Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and people with excess body weight.
- Trial name
- NCT06718998
- Testing
- NNC0519-0130
- Where
- Austria
- Volunteers
- 134 people
- Sponsor
- Novo Nordisk A/S
Healhty, Overweight or Obesity
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812…
- Trial name
- NCT07224399
- Testing
- BGM1812
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Non-diabetic Overweight or Obese
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC)…
- Trial name
- NCT06714955
- Testing
- Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
- Trial name
- NCT05406115
- Testing
- AMG 786
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Amgen
Obesity
Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy
This study will provide clinical data in an observational setting. Individuals undergoing LSG, and who meet study entry criteria, may be enrolled.
- Trial name
- NCT02358785
- Testing
- ECHELON FLEX™ Powered Plus Stapler
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ethicon Endo-Surgery
Healthy, Overweight and Obese Adults
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
- Trial name
- NCT07307274
- Testing
- SYNT101
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Syntis Bio
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Choline Deficiency, Liver Injury
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
TARA-001-301 is a Phase 2b/3 randomized Open-Label Dose-Selection study with an Open-Label Extension and randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to investigate the safety and efficacy of…
- Trial name
- THRIVE-3 (NCT06910943)
- Testing
- Choline Chloride for Injection
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 129 people
- Sponsor
- Protara Therapeutics
Overweight or Obesity
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
- Trial name
- NCT06830343
- Testing
- SYH9017, Wegovy ®
- Where
- China
- Volunteers
- 66 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss.
- Trial name
- TRIUMPH-6 (NCT06859268)
- Testing
- Retatrutide
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Nutritional Status
A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.
This methodology study will evaluate the sensitivity in using sitting knee digital caliper to measure changes in sitting knee length from over a 12-week study period amidst children in the age of 6 to 12 years in a…
- Trial name
- NCT02201225
- Testing
- Nutritional supplement with micronutrient, Nutritional supplement without micronutrient
- Where
- India
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Morbid, Liver Fibrosis
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
Non-Alcoholic Fatty Liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight.
- Trial name
- NCT03872024
- Testing
- For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model, From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Echosens
Obesity
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
The study evaluated the safety and efficacy of the vBloc Therapy delivered by the Maestro Rechargeable System compared to a sham control for the treatment obesity.
- Trial name
- ReCharge (NCT01327976)
- Testing
- vBloc (Active Device)
- Where
- 10 sites in United States, Australia
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Obesity
Safety Study to Evaluate BMS-830216 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects
- Trial name
- NCT00878020
- Testing
- BMS-830216
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight, Obesity
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet.
- Trial name
- NCT04086797
- Testing
- IQP-AE-103
- Where
- Germany
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Overweight , Obesity
A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants
This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal…
- Trial name
- NCT07443059
- Testing
- Zovaglutide
- Where
- 3 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity/Overweight
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in…
- Trial name
- NCT07017179
- Testing
- AZD6234, AZD9550, Plocebo
- Where
- 3 sites in China
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese…
- Trial name
- NCT06628362
- Testing
- Enicepatide
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 447 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity and Cardiovascular Risk
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation.
- Trial name
- QUELL-CV (NCT07656727)
- Testing
- Oral BGE-102
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- BioAge Labs, Inc.